Stay updated on HPV Immunotherapy in Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the HPV Immunotherapy in Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the HPV Immunotherapy in Head and Neck Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the number of participants experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) in a study related to HPV Specific Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:27:48.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 6 to 7, indicating an update in the number of participants or a related metric in the study of HPV specific immunotherapy for head and neck squamous cell carcinoma. This change is significant for those tracking the progress and results of this medical research.
    Difference
    0.2%
    Check dated 2024-05-22T20:59:11.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    8%
    Check dated 2024-04-30T21:53:56.000Z thumbnail image

Stay in the know with updates to HPV Immunotherapy in Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the HPV Immunotherapy in Head and Neck Cancer Clinical Trial page.